1. Introduction

   • Kenneth P. Johnson

   EditorialNotes Pages: S1 - S2

2. A review of the clinical efficacy profile of copolymer 1: New U.S. phase III trial data

   • Kenneth P. Johnson

   OriginalPaper Pages: S3 - S7

3. New insights into the mechanism of action of copolymer 1 of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis

   • Ruth Arnon
   • Michael Sela
   • Dvora Teitelbaum

   OriginalPaper Pages: S8 - S13

4. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease

   • Avraham Ben-Nun
   • Itzhack Mendel
   • Nicole Kerlero de Rosbo

   OriginalPaper Pages: S14 - S22

5. Safety profile of copolymer 1: Analysis of cumulative experience in the United States and Israel

   • Amos D. Korczyn
   • Puiu Nisipeanu

   OriginalPaper Pages: S23 - S26